Petosemtamab for laryngeal diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Jul 2024: Trial registered, NCT06525220
  2. 25 Sep 2024: Trial started, NCT06525220

The trials

NCT06525220: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

State
Under way
Phase
Phase 3
People
699 taking part
Started
25 Sep 2024
Primary completion
Jan 2028
Arms
Petosemtamab + Pembrolizumab
Results
None posted
  1. 29 Jul 2024: Trial registered
  2. 25 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX, MCLA-158 + Pembrolizumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.